MAP3K14 and diabetes mellitus: By comparison, patients in the END group had a higher prevalence of diabetes mellitus (DM; 41% vs. 19%, p = 0.001), higher median baseline NIHSS scores (5 vs. 2, p = 0.001), and higher hs‐CRP levels (5.6 vs. 1.7, p = 0.016).